Stock Analysis

Biosino Bio-Technology and Science Incorporation Third Quarter 2023 Earnings: CN¥0.004 loss per share (vs CN¥0.074 profit in 3Q 2022)

Published
SEHK:8247

Biosino Bio-Technology and Science Incorporation (HKG:8247) Third Quarter 2023 Results

Key Financial Results

  • Revenue: CN¥71.4m (down 31% from 3Q 2022).
  • Net loss: CN¥569.0k (down by 105% from CN¥10.7m profit in 3Q 2022).
  • CN¥0.004 loss per share (down from CN¥0.074 profit in 3Q 2022).
SEHK:8247 Earnings and Revenue History November 16th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biosino Bio-Technology and Science Incorporation's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Biosino Bio-Technology and Science Incorporation.

Valuation is complex, but we're here to simplify it.

Discover if Biosino Bio-Technology and Science Incorporation might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.